Sex Differences in Blood Pressure-Lowering Therapy and Outcomes Following Intracerebral Hemorrhage: Results From ATACH-2.


Journal

Stroke
ISSN: 1524-4628
Titre abrégé: Stroke
Pays: United States
ID NLM: 0235266

Informations de publication

Date de publication:
08 2020
Historique:
pubmed: 7 7 2020
medline: 5 11 2020
entrez: 7 7 2020
Statut: ppublish

Résumé

Evidence regarding sex differences in clinical outcomes and treatment effect following intracerebral hemorrhage is limited. Using the ATACH-2 trial (Antihypertensive Treatment in Intracerebral Hemorrhage-2) data, we explored whether sex disparities exist in outcomes and response to intensive blood pressure (BP)-lowering therapy. Eligible intracerebral hemorrhage subjects were randomly assigned to intensive (target systolic BP, 110-139 mm Hg) or standard (140-179 mm Hg) BP-lowering therapy within 4.5 hours after onset. Relative risk of death or disability corresponding to the modified Rankin Scale score of 4 to 6 was calculated, and interaction between sex and treatment was explored. In total, 380 women and 620 men were included. Women were older, more prescribed antihypertensive drugs before onset, and had more lobar intracerebral hemorrhage than men. Hematoma expansion was observed less in women. After multivariable adjustment, the relative risk of death or disability in women was 1.19 (95% CI, 1.02-1.37, Women had a higher risk of death or disability following intracerebral hemorrhage. The benefit of intensive BP-lowering therapy in women is inconclusive, consistent with the overall results of ATACH-2. Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01176565.

Sections du résumé

BACKGROUND AND PURPOSE
Evidence regarding sex differences in clinical outcomes and treatment effect following intracerebral hemorrhage is limited. Using the ATACH-2 trial (Antihypertensive Treatment in Intracerebral Hemorrhage-2) data, we explored whether sex disparities exist in outcomes and response to intensive blood pressure (BP)-lowering therapy.
METHODS
Eligible intracerebral hemorrhage subjects were randomly assigned to intensive (target systolic BP, 110-139 mm Hg) or standard (140-179 mm Hg) BP-lowering therapy within 4.5 hours after onset. Relative risk of death or disability corresponding to the modified Rankin Scale score of 4 to 6 was calculated, and interaction between sex and treatment was explored.
RESULTS
In total, 380 women and 620 men were included. Women were older, more prescribed antihypertensive drugs before onset, and had more lobar intracerebral hemorrhage than men. Hematoma expansion was observed less in women. After multivariable adjustment, the relative risk of death or disability in women was 1.19 (95% CI, 1.02-1.37,
CONCLUSIONS
Women had a higher risk of death or disability following intracerebral hemorrhage. The benefit of intensive BP-lowering therapy in women is inconclusive, consistent with the overall results of ATACH-2. Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01176565.

Identifiants

pubmed: 32623977
doi: 10.1161/STROKEAHA.120.029770
pmc: PMC9371624
mid: NIHMS1603566
doi:

Substances chimiques

Antihypertensive Agents 0

Banques de données

ClinicalTrials.gov
['NCT01176565']

Types de publication

Journal Article Multicenter Study Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2282-2286

Subventions

Organisme : NINDS NIH HHS
ID : U01 NS059041
Pays : United States
Organisme : NINDS NIH HHS
ID : U01 NS061861
Pays : United States
Organisme : NINDS NIH HHS
ID : U01 NS062091
Pays : United States

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Références

N Engl J Med. 2013 Jun 20;368(25):2355-65
pubmed: 23713578
Stroke. 2019 Jun;50(6):1626-1633
pubmed: 31043154
JAMA Neurol. 2017 Dec 1;74(12):1439-1445
pubmed: 29059266
Qual Life Res. 2019 Aug;28(8):2041-2056
pubmed: 30875008
Stroke. 2019 Aug;50(8):2016-2022
pubmed: 31272326
Heart. 2018 Sep;104(18):1536-1542
pubmed: 29588329
N Engl J Med. 2016 Sep 15;375(11):1033-43
pubmed: 27276234
Nat Rev Neurol. 2017 Sep;13(9):521-532
pubmed: 28731036
Neurology. 2006 Apr 25;66(8):1175-81
pubmed: 16636233
Stroke. 2018 Mar;49(3):531-535
pubmed: 29438087
Neurology. 2019 Dec 10;93(24):e2170-e2180
pubmed: 31719135
JAMA Netw Open. 2019 Aug 2;2(8):e198398
pubmed: 31373653

Auteurs

Mayumi Fukuda-Doi (M)

Department of Cerebrovascular Medicine (M.F.-D., M.K., S.Y., K.M., K.T.), National Cerebral and Cardiovascular Center, Suita, Japan.
Center for Advancing Clinical and Translational Sciences (M.F.-D., H.Y.), National Cerebral and Cardiovascular Center, Suita, Japan.
Department of Neurology, Keio University School of Medicine, Tokyo, Japan (M.F.-D., J.N., N.S., K.T.).

Haruko Yamamoto (H)

Center for Advancing Clinical and Translational Sciences (M.F.-D., H.Y.), National Cerebral and Cardiovascular Center, Suita, Japan.

Masatoshi Koga (M)

Department of Cerebrovascular Medicine (M.F.-D., M.K., S.Y., K.M., K.T.), National Cerebral and Cardiovascular Center, Suita, Japan.

Yuko Y Palesch (YY)

Department of Public Health Sciences, Medical University of South Carolina, Charleston (Y.Y.P., V.L.D.-M.).

Valerie L Durkalski-Mauldin (VL)

Department of Public Health Sciences, Medical University of South Carolina, Charleston (Y.Y.P., V.L.D.-M.).

Adnan I Qureshi (AI)

Zeenat Qureshi Stroke Institute, St. Cloud, MN (A.I.Q.).
Department of Neurology, University of Missouri, Columbia (A.I.Q.).

Sohei Yoshimura (S)

Department of Cerebrovascular Medicine (M.F.-D., M.K., S.Y., K.M., K.T.), National Cerebral and Cardiovascular Center, Suita, Japan.

Shuhei Okazaki (S)

Department of Neurology (S. Okazaki), National Cerebral and Cardiovascular Center, Suita, Japan.

Kaori Miwa (K)

Department of Cerebrovascular Medicine (M.F.-D., M.K., S.Y., K.M., K.T.), National Cerebral and Cardiovascular Center, Suita, Japan.

Yasushi Okada (Y)

Department of Cerebrovascular Medicine and Neurology, National Hospital Organization Kyushu Medical Center Clinical Research Institute, Fukuoka, Japan (Y.O.).

Toshihiro Ueda (T)

Department of Strokology, Stroke Center, St. Marianna University Toyoko Hospital, Kawasaki, Japan (T.U.).

Satoshi Okuda (S)

Department of Neurology, National Hospital Organization Nagoya Medical Center, Japan (S. Okuda).

Jin Nakahara (J)

Department of Neurology, Keio University School of Medicine, Tokyo, Japan (M.F.-D., J.N., N.S., K.T.).

Norihiro Suzuki (N)

Department of Neurology, Keio University School of Medicine, Tokyo, Japan (M.F.-D., J.N., N.S., K.T.).

Kazunori Toyoda (K)

Department of Cerebrovascular Medicine (M.F.-D., M.K., S.Y., K.M., K.T.), National Cerebral and Cardiovascular Center, Suita, Japan.
Department of Neurology, Keio University School of Medicine, Tokyo, Japan (M.F.-D., J.N., N.S., K.T.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH